OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Landgren on the Clinical Benefit of Idecabtagene Vicleucel in R/R Myeloma

July 1st 2020

C. Ola Landgren, MD, PhD, discusses the efficacy of idecabtagene vicleucel in the treatment of patients with relapsed/refractory myeloma.

Dr. Al-Sawaf on Fixed-Duration Versus Continuous Treatment in CLL

July 1st 2020

Othman Al-Sawaf, MD, discusses benefits of a fixed duration treatment versus continuous treatment in chronic lymphocytic leukemia.

Dr. Verstovsek on Limitations of the Current Treatment Landscape of Myelofibrosis

July 1st 2020

Srdan Verstovsek, MD, PhD, discusses the limitations of the current treatment landscape of myelofibrosis.

Dr. Monk on the Utility of Tisotumab Vedotin in Recurrent Cervical Cancer

July 1st 2020

Bradley J. Monk, MD, FACS, FACOG, discusses the utility of tisotumab vedotin in recurrent cervical cancer.

Dr. Shore on the Safety Profiles of Relugolix and Leuprolide in Prostate Cancer

July 1st 2020

​Neal D. Shore, MD, FACS, discusses the safety profiles of relugolix and leuprolide in advanced prostate cancer.

Dr. Schwartz on ​the Results of the Alliance A091401 Study in Metastatic Sarcoma

July 1st 2020

Gary K. Schwartz, MD, discusses results of the Alliance A091401 trial (NCT02500797) in patients with metastatic sarcoma.

Dr. Sangro on Updated Findings From the CheckMate-459 Trial in Advanced HCC

July 1st 2020

Bruno Sangro, MD, PhD, discusses the updated findings from the phase 3 CheckMate-459 trial, which evaluated the use of nivolumab and sorafenib in the treatment of patients with advanced hepatocellular carcinoma.

Dr. Ruan on the Utility of Molecular Profiling in Mantle Cell Lymphoma

June 30th 2020

Jia Ruan, MD, PhD, discusses ​the utility of molecular profiling in mantle cell lymphoma.

Dr. Roué on the Synergistic Activity With TG-1701, Ublituximab, and Umbralisib in MCL

June 30th 2020

Gaël Roué, PhD, discusses the synergistic activity with TG-1701, ublituximab, and umbralisib in ibrutinib-resistant mantle cell lymphoma models.

Dr. Rana on the Prevalence of Pathogenic Variants in Prostate Cancer

June 30th 2020

Huma Q. Rana, MD, MPH, discusses the prevalence of pathogenic variants in patients with prostate cancer enrolled on the ProGen study.

Dr. Costello on the Role of Daratumumab in Multiple Myeloma

June 30th 2020

Caitlin Costello, MD, discusses the role of daratumumab in multiple myeloma.

Dr. Munshi on the Current Landscape of CAR T-Cell Therapy in Multiple Myeloma

June 30th 2020

Nikhil C. Munshi, MD, discusses the role of CAR T-cell therapy in relapsed/refractory multiple myeloma.

Dr. Kumar on Stem Cell Mobilization in Multiple Myeloma

June 30th 2020

Shaji K. Kumar, MD, discusses stem cell mobilization multiple myeloma.

Dr. Weisel on the Safety Profile of Isa-KRd in High-Risk Multiple Myeloma

June 30th 2020

Katja Weisel, MD, discusses the safety profile of isatuximab-irfc in combination with carfilzomib, lenalidomide, and dexamethasone in high-risk patients with newly diagnosed multiple myeloma.

Dr. Landgren on Investigational Cellular Therapies in Multiple Myeloma

June 30th 2020

C. Ola Landgren, MD, PhD, discusses investigational cellular therapies in multiple myeloma.

Dr. Costa on CC-93269 in Relapsed/Refractory Multiple Myeloma

June 29th 2020

Luciano J. Costa, MD, PhD, sheds light on CC-93269, a BCMA 2+1 T-cell engager, under examination in a phase 1 dose-finding study in relapsed/refractory multiple myeloma.

Dr. Jacobson on the Next Steps With Axi-Cel in R/R Indolent Non-Hodgkin Lymphoma

June 29th 2020

Caron Jacobson, MD, discusses the next steps with axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma.

Dr. Welslau on the Rationale for Rituximab Biosimilar Combination in DLBCL

June 29th 2020

Manfred Welslau, MD, discusses the rationale for investigating the Sandoz rituximab biosimilar, Rixathon, in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone in diffuse large B-cell lymphoma.

Dr. Neelapu on the Safety Profile of ALLO-501 Plus ALLO-647 in R/R B-Cell Lymphomas

June 29th 2020

Sattva Neelapu, MD, discusses the safety profile of ALLO-501 in combination with ALLO-647 in patients with relapsed/refractory large B-cell lymphoma or follicular lymphoma.

Dr. Saad on Unanswered Questions From the SPARTAN Trial in M0CRPC

June 29th 2020

Fred Saad, MD, FRCS, discusses unanswered questions from the randomized phase 3 SPARTAN trial in nonmetastatic castration-resistant prostate cancer.

NEXT PAGE
PREVIOUS PAGE